Analysts Perspectives: Dynavax Technologies (DVAX)

Adjust Comment Print

According to analysts Dynavax Technologies (NASDAQ:DVAX)'s minimum EPS for the current quarter is at $-0.48 and can go high up to $1.24. They expect this year's earnings to fall -41.1% year-over-year to -$1.72, followed by -40.12% decline in the next year to -$1.03. While in the same Quarter Previous year, the Actual EPS was $-0.56. During the same period last year, the company posted ($0.90) earnings per share. analysts anticipate that Dynavax Technologies Corporation will post -1.72 earnings per share for the current year.

In the most updated research from a number of analysts on Wall Street, the company gets 5 Buys and 0 Sell among 5 analysts. Dynavax Technologies Corp. The business had revenue of $2.65 million for the quarter, compared to the consensus estimate of $1.58 million.

Dynavax Technologies Corporation (DVAX) has the market capitalization of $1.1 Billion. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.15. The days to cover decreased to 5.0 and the percentage of shorted shares was 0.13% on October 13. Dynavax Technologies Corporation had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. Vanguard Group Inc. now owns 2,024,666 shares of the biopharmaceutical company's stock worth $19,538,000 after buying an additional 199,004 shares during the period.

DVAX has been the subject of a number of recent analyst reports.

Dynavax Technologies Corporation (NASDAQ:DVAX)'s earnings per share has been growing at a 5.5 percent rate over the past 5 year when average revenue increase was noted as -12.6 percent. William Blair reissued an "outperform" rating and issued a $30.00 price target on shares of Dynavax Technologies Corporation in a report on Wednesday, August 9th. Finally, J P Morgan Chase & Co raised Dynavax Technologies Corporation from a "neutral" rating to an "overweight" rating and increased their price target for the company from $6.00 to $27.00 in a research note on Monday, July 31st.

Jack Sock beats Marin Cilic in straight sets at ATP Finals
Jack Sock has revealed that he was forced out of his room at 4am on Tuesday morning due to a fire alarm at his hotel. The No. 8-seeded player defeated Wimbledon finalist Marin Cilic 5-7, 6-2, 7-6 (4) on Tuesday.

November 9 investment analysts at Cantor Fitzgerald held the stock rating at "Buy" projecting a price of $25.00. The third largest holder is Gmt Capital Corp, which now holds $61.91 million worth of this stock and that ownership represents almost 5.63% of its market capitalization. If you are viewing this report on another domain, it was illegally copied and reposted in violation of USA & global copyright & trademark legislation. The correct version of this article can be read at Dynavax Technologies Corporation (NASDAQ:DVAX)'s short interest is 7.63 million shares, or 17.27% of the float. The portion of a company's profit allocated to each outstanding share of common stock was $1.64 a share in the trailing twelve months. The recent change has given its price a -13.52% deficit over SMA 50 and -24.95% deficit over its 52-week high.

Large investors have recently made changes to their positions in the company.

On the other hand Dynavax Technologies (NASDAQ:DVAX) has Relative Strength Index (RSI 14) of 35.75 along with Average True Range (ATR 14) of 1.48.

Insider ownership increased by a total of 0 shares, which suggests that DVAX's key executives are feeling more optimistic about the outlook for the stock. Candriam Luxembourg S.C.A. bought a new stake in shares of Dynavax Technologies Corporation in the 2nd quarter valued at approximately $5,066,000. Rathbone Brothers plc purchased a new stake in shares of Dynavax Technologies Corp. during the third quarter valued at approximately $105,000.

Dynavax Technologies Corporation is a clinical-stage immunotherapy company.